Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Abril-Rodriguez

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Cancer Cell|June 14, 2017
SnapShot: Immune Checkpoint InhibitorsGabriel Abril-Rodriguez, Antoni Ribas
Cancer Immunology Research|October 6, 2023
Antitumor Immune Responses in B2M-Deficient CancersDavis Y Torrejon, Mildred Galvez, Gabriel Abril-Rodriguez, et al.
JCI Insight|August 26, 2020
IL-32γ potentiates tumor immunity in melanomaThomas Gruber, Mirela Kremenovic, Hassan Sadozai, et al.
The Journal of Clinical Investigation|April 29, 2021
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapyYeon Joo Kim, Katherine M Sheu, Jennifer Tsoi, et al.
Cell Reports|December 12, 2019
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 ExpressionAngel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.
Cell Reports|May 13, 2017
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 ExpressionAngel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.
Nature Communications|February 9, 2024
CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypesSameeha Jilani, Justin D Saco, Edurne Mugarza, et al.
Nature Cancer|August 9, 2021
PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Nature Cancer|February 5, 2022
Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Cancer Discovery|May 30, 2020
Overcoming Genetically Based Resistance Mechanisms to PD-1 BlockadeDavis Y Torrejon, Gabriel Abril-Rodriguez, Ameya S Champhekar, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Cancer Cell|June 14, 2017
SnapShot: Immune Checkpoint InhibitorsGabriel Abril-Rodriguez, Antoni Ribas
Cancer Immunology Research|October 6, 2023
Antitumor Immune Responses in B2M-Deficient CancersDavis Y Torrejon, Mildred Galvez, Gabriel Abril-Rodriguez, et al.
JCI Insight|August 26, 2020
IL-32γ potentiates tumor immunity in melanomaThomas Gruber, Mirela Kremenovic, Hassan Sadozai, et al.
The Journal of Clinical Investigation|April 29, 2021
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapyYeon Joo Kim, Katherine M Sheu, Jennifer Tsoi, et al.
Cell Reports|December 12, 2019
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 ExpressionAngel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.
Cell Reports|May 13, 2017
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 ExpressionAngel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.
Nature Communications|February 9, 2024
CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypesSameeha Jilani, Justin D Saco, Edurne Mugarza, et al.
Nature Cancer|August 9, 2021
PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Nature Cancer|February 5, 2022
Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Cancer Discovery|May 30, 2020
Overcoming Genetically Based Resistance Mechanisms to PD-1 BlockadeDavis Y Torrejon, Gabriel Abril-Rodriguez, Ameya S Champhekar, et al.
Pageof 2